Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Rasmussen, MH, Jensen, N, Tarpgaard, LS, Qvortrup, C, Rømer, MUK, Stenvang, J, Hansen, T, Christensen, LL, Lindebjerg, J, Hansen, F, Jensen, BV, Hansen, T, Pfeiffer, P, Brünner, NA, Ørntoft, TF & Andersen, C 2013, 'High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer', Molecular Oncology, bind 7, nr. 3, s. 637-46. https://doi.org/10.1016/j.molonc.2013.02.016

APA

Rasmussen, M. H., Jensen, N., Tarpgaard, L. S., Qvortrup, C., Rømer, M. U. K., Stenvang, J., Hansen, T., Christensen, L. L., Lindebjerg, J., Hansen, F., Jensen, B. V., Hansen, T., Pfeiffer, P., Brünner, N. A., Ørntoft, T. F., & Andersen, C. (2013). High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Molecular Oncology, 7(3), 637-46. https://doi.org/10.1016/j.molonc.2013.02.016

CBE

Rasmussen MH, Jensen N, Tarpgaard LS, Qvortrup C, Rømer MUK, Stenvang J, Hansen T, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen T, Pfeiffer P, Brünner NA, Ørntoft TF, Andersen C. 2013. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Molecular Oncology. 7(3):637-46. https://doi.org/10.1016/j.molonc.2013.02.016

MLA

Vancouver

Author

Rasmussen, Mads Heilskov ; Jensen, Niels ; Tarpgaard, Line Schmidt ; Qvortrup, Camilla ; Rømer, Maria Unni Koefoed ; Stenvang, Jan ; Hansen, Tine ; Christensen, Lise L ; Lindebjerg, Jan ; Hansen, Flemming ; Jensen, Benny V ; Hansen, Torben ; Pfeiffer, Per ; Brünner, Nils Aage ; Ørntoft, Torben Falck ; Andersen, Claus. / High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. I: Molecular Oncology. 2013 ; Bind 7, Nr. 3. s. 637-46.

Bibtex

@article{0dea35de3b154d3bacd591c0e54c523d,
title = "High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer",
abstract = "The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin (XELOX/FOLFOX) or irinotecan (XELIRI/FOLFIRI). With an overall objective response rate of approximately 50% for either treatment combination, a major unsolved problem is that no predictors of response to these treatments are available. To address this issue, we profiled 742 microRNAs in laser-capture microdissected cancer cells from responding and non-responding patients receiving XELOX/FOLFOX as first-line treatment for mCRC, and identified, among others, high expression of miR-625-3p, miR-181b and miR-27b to be associated with poor clinical response. In a validation cohort of 94 mCRC patients treated first-line with XELOX, high expression of miR-625-3p was confirmed to be associated with poor response (OR = 6.25, 95%CI [1.8; 21.0]). Independent analyses showed that miR-625-3p was not dysregulated between normal and cancer samples, nor was its expression associated with recurrence of stage II or III disease, indicating that miR-625-3p solely is a response marker. Finally, we also found that these miRNAs were up-regulated in oxaliplatin resistant HCT116/oxPt (miR-625-3p, miR-181b and miR-27b) and LoVo/oxPt (miR-181b) colon cancer cell lines as compared with their isogenic parental cells. Altogether, our results suggest an association between miR-625-3p and response to first-line oxaliplatin based chemotherapy of mCRC.",
author = "Rasmussen, {Mads Heilskov} and Niels Jensen and Tarpgaard, {Line Schmidt} and Camilla Qvortrup and R{\o}mer, {Maria Unni Koefoed} and Jan Stenvang and Tine Hansen and Christensen, {Lise L} and Jan Lindebjerg and Flemming Hansen and Jensen, {Benny V} and Torben Hansen and Per Pfeiffer and Br{\"u}nner, {Nils Aage} and {\O}rntoft, {Torben Falck} and Claus Andersen",
note = "Copyright {\textcopyright} 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.",
year = "2013",
month = jun,
doi = "10.1016/j.molonc.2013.02.016",
language = "English",
volume = "7",
pages = "637--46",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier BV",
number = "3",

}

RIS

TY - JOUR

T1 - High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer

AU - Rasmussen, Mads Heilskov

AU - Jensen, Niels

AU - Tarpgaard, Line Schmidt

AU - Qvortrup, Camilla

AU - Rømer, Maria Unni Koefoed

AU - Stenvang, Jan

AU - Hansen, Tine

AU - Christensen, Lise L

AU - Lindebjerg, Jan

AU - Hansen, Flemming

AU - Jensen, Benny V

AU - Hansen, Torben

AU - Pfeiffer, Per

AU - Brünner, Nils Aage

AU - Ørntoft, Torben Falck

AU - Andersen, Claus

N1 - Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

PY - 2013/6

Y1 - 2013/6

N2 - The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin (XELOX/FOLFOX) or irinotecan (XELIRI/FOLFIRI). With an overall objective response rate of approximately 50% for either treatment combination, a major unsolved problem is that no predictors of response to these treatments are available. To address this issue, we profiled 742 microRNAs in laser-capture microdissected cancer cells from responding and non-responding patients receiving XELOX/FOLFOX as first-line treatment for mCRC, and identified, among others, high expression of miR-625-3p, miR-181b and miR-27b to be associated with poor clinical response. In a validation cohort of 94 mCRC patients treated first-line with XELOX, high expression of miR-625-3p was confirmed to be associated with poor response (OR = 6.25, 95%CI [1.8; 21.0]). Independent analyses showed that miR-625-3p was not dysregulated between normal and cancer samples, nor was its expression associated with recurrence of stage II or III disease, indicating that miR-625-3p solely is a response marker. Finally, we also found that these miRNAs were up-regulated in oxaliplatin resistant HCT116/oxPt (miR-625-3p, miR-181b and miR-27b) and LoVo/oxPt (miR-181b) colon cancer cell lines as compared with their isogenic parental cells. Altogether, our results suggest an association between miR-625-3p and response to first-line oxaliplatin based chemotherapy of mCRC.

AB - The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin (XELOX/FOLFOX) or irinotecan (XELIRI/FOLFIRI). With an overall objective response rate of approximately 50% for either treatment combination, a major unsolved problem is that no predictors of response to these treatments are available. To address this issue, we profiled 742 microRNAs in laser-capture microdissected cancer cells from responding and non-responding patients receiving XELOX/FOLFOX as first-line treatment for mCRC, and identified, among others, high expression of miR-625-3p, miR-181b and miR-27b to be associated with poor clinical response. In a validation cohort of 94 mCRC patients treated first-line with XELOX, high expression of miR-625-3p was confirmed to be associated with poor response (OR = 6.25, 95%CI [1.8; 21.0]). Independent analyses showed that miR-625-3p was not dysregulated between normal and cancer samples, nor was its expression associated with recurrence of stage II or III disease, indicating that miR-625-3p solely is a response marker. Finally, we also found that these miRNAs were up-regulated in oxaliplatin resistant HCT116/oxPt (miR-625-3p, miR-181b and miR-27b) and LoVo/oxPt (miR-181b) colon cancer cell lines as compared with their isogenic parental cells. Altogether, our results suggest an association between miR-625-3p and response to first-line oxaliplatin based chemotherapy of mCRC.

U2 - 10.1016/j.molonc.2013.02.016

DO - 10.1016/j.molonc.2013.02.016

M3 - Journal article

C2 - 23506979

VL - 7

SP - 637

EP - 646

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 3

ER -

ID: 39766079